the Subcommittee on Oversight and Investigations House Committee on Energy and Commerce March 26 2009.
| Předmět: | |
|---|---|
| Zdroj: | Biomedical Market Newsletter; 3/7/2011, p472-478, 7p |
| Abstrakt: | The article presents a speech by Joanne Less, director of the Good Clinical Practice Program in the Office of the Commissioner, the U.S. Food & Drug Administration (FDA), delivered before the Subcommittee on Oversight and Investigations and House Committee on Energy and Commerce, held on March 26, 2009, in which he discussed the role of FDA in overseeing Institutional Review Boards (IRBs). |
| Databáze: | Complementary Index |
| Externí odkaz: |
|